The selective phosphodiesterase 4 inhibitor roflumilast and phosphodiesterase 3/4 inhibitor pumafentrine reduce clinical score and TNF expression in experimental colitis in mice. [PDF]
, 2013 The specific inhibition of phosphodiesterase (PDE)4 and dual inhibition of PDE3 and PDE4 has been shown to decrease inflammation by suppression of pro-inflammatory cytokine synthesis.
A Hatzelmann +43 more
core +4 more sources
Pulmonary Circulation, 2020 Phosphodiesterase-5 inhibitors are commonly used in pulmonary arterial hypertension but, as suggested by the RESPITE study, phosphodiesterase-5 inhibitor therapy (mono-/combination) does not always have a satisfactory treatment effect.
Clara Hjalmarsson +8 more
doaj +1 more source
Compartmentalized PDE4A5 signaling impairs hippocampal synaptic plasticity and long-term memory [PDF]
, 2016 Alterations in cAMP signaling are thought to contribute to neurocognitive and neuropsychiatric disorders. Members of the cAMP-specific phosphodiesterase 4 (PDE4) family, which contains >25 different isoforms, play a key role in determining spatial ...
Abel, Ted +13 more
core +5 more sources
Phosphodiesterase 4 Inhibitors in Allergic Rhinitis/Rhinosinusitis
Frontiers in Pharmacology, 2020 Allergic rhinitis/rhinosinusitis (AR) is the most common allergic disease. It affects patients’ quality of life and may influence the severity of lower airway disease such as asthma. Therefore, its treatment is of great importance.
Viera Janosova +5 more
doaj +1 more source
Activity of Cyclic AMP Phosphodiesterases and Adenylyl Cyclase in Peripheral Nerve after Crush and Permanent Transection Injuries [PDF]
, 1998 Recent studies demonstrate that cAMP levels are tightly controlled during demyelination and remyelination in Schwann cells as cAMP decreases to 8–10% of normal following both sciatic nerve crush or permanent transection injury and only begins to increase
Poduslo, Joseph F. +1 more
core +1 more source
Endothelial dysfunction markers as a therapeutic target for Sildenafil treatment and effects on metabolic control in type 2 diabetes [PDF]
, 2015 Endothelial dysfunction (ED) plays a role in diabetic cardiovascular complications. Hyperglycemia increases cytockines involved in vascular inflammation.
Bertolini, Camilla +10 more
core +1 more source
Selective inhibition of phosphodiesterases 4, 5 and 9 induces HSP20 phosphorylation and attenuates amyloid beta 1-42 mediated cytotoxicity [PDF]
, 2016 Phosphodiesterase (PDE) inhibitors are currently under evaluation as agents that may facilitate the improvement of cognitive impairment associated with Alzheimer's disease. Our aim was to determine whether inhibitors of PDEs 4,5 and 9 could alleviate the
Baillie, George S. +4 more
core +1 more source
PDE5 inhibitor drugs for use in dementia
Alzheimer’s & Dementia: Translational Research & Clinical Interventions, 2023 Alzheimer's disease and related dementias (ADRD) remain a major health‐care challenge with few licensed medications. Repurposing existing drugs may afford prevention and treatment.
Atticus H. Hainsworth +4 more
doaj +1 more source
Phosphodiesterase-5 inhibitors: Raynaud's and beyond
Indian Journal of Rheumatology, 2017 Phosphodiesterases (PDE) are a group of ubiquitously present enzymes involved in regulation of various cellular pathways. PDE5 acts to metabolize cyclic guanosine monophosphate (GMP).
Sanat Phatak +3 more
doaj +2 more sources
Nonsteroidal anti-inflammatory drugs as potential ecto-nucleotide phosphodiesterase inhibitors
Brazilian Journal of Pharmaceutical Sciences, 2020 Phosphodiesterases (PDE) are group of enzymes which catalyze the hydrolysis of cAMP and cGMP. Since these cyclic phosphate moieties worked as intracellular second messengers in numerous physiological processes, their inhibition can affect normal ...
Shumaila Tasneem +2 more
doaj +1 more source